Skip to main content

Table 3 Comparison of angiogenesis cytokines among RS3PE with/without malignancy, OA, and EORA

From: bFGF could be a biomarker of malignancy in RS3PE syndrome: an ambispective single-center cohort analysis of 51 patients

 

RS3PE with malignancy (n = 8)

RS3PE without malignancy (n = 38)

OA (n = 15)

EORA (n = 14)

F/t

P

Flt-1 (ng/mL)

7.38±2.64

6.14±2.25

5.96±1.53

5.59±1.67

1.321

0.275

PlGF (ng/mL)

6.14 (4.436, 6.58)

5.99 (4.45, 7.29)

5.61(4.74, 6.6)

4.81 (4.48, 7.15)

0.745

0.863

Tie-2 (ng/mL)

8.99±2.34

9.92±2.89

11.26±2.72

8.47±2.41

2.816

0.045

VEGF (ng/mL)

168.41 (90.86, 327.61)

83.15 (50.34, 200.11)

156.24 (117.94, 239.03)

71.68 (40.74, 234.95)

4.144

0.246

VEGF-C (ng/mL)

3.76 (1.69, 7.58)

4.75 (3.72, 9.79)

6.57 (5.45, 7.82)

5.31 (3.87, 6.46)

3.281

0.350

VEGF-D (ng/mL)

18.40 (14.86, 30.31)

31.92 (26.88, 46.75)

26.43 (23.64, 36.74)

24.98 (17.56, 34.74)

10.433

0.015

bFGF (ng/mL)

14.21 (7.52, 23.18)

4.32 (2.88, 7.42)

3.23 (1.96, 5.59)

3.20 (2.20, 5.30)

15.861

0.001

MMP-3 (ng/mL)

24.74 (17.96, 51.67)

36.08 (19.01, 54.34)

22.03 (14.84, 25.57)

33.31 (15.86, 41.44)

5.346

0.148

MMP-1 (ng/mL)

4.98 (3.80, 7.50)

3.93 (1.94, 7.73)

2.90 (1.72, 4.50)

5.80 (3.37, 10.73)

5.472

0.140

MMP-7 (ng/mL)

2.11 (1.55, 5.02)

2.86 (1.99, 3.40)

2.68 (1.64, 4.16)

3.06 (2.02, 5.03)

0.864

0.834

TRAIL (pg/mL)

82.28 (57.26, 121.38)

93.86 (75.98, 140.34)

98.56 (84.51, 114.28)

89.96 (61.04, 124.94)

2.324

0.508

Mesothelin (ng/mL)

25.65 (17.81, 34.84)

24.10 (17.89, 30.54)

27.20 (15.40, 30.27)

21.96 (18.94, 28.50)

0.688

0.876

  1. Note: Significance comparing with RS3PEpatients with malignancy, adjusted P<0.05. RS3PE remitting seronegative symmetrical synovitis with pitting edema, Flt-1 Fms-like tyrosine kinase 1, VEGF vascular endothelial growth factor, PIGF placental growth factor, bFGF basic fibroblast growth factor, MMP matrix metalloproteinase, TRAIL tumor necrosis factor-related apoptosis-inducing ligand